Overview

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
All
Summary
This study is to describe the safety and efficacy of Xyntha® during the usual care setting.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Factor VIII
Criteria
Inclusion Criteria:

- Patients or legally authorized representatives of pediatric patients agree to provide
written informed consent form (data privacy statement).

- Pediatric and adult patients who have been treated with Xyntha for Hemophilia A from
first approved date by KFDA, or who are planned to be newly prescribed Xyntha.

Exclusion Criteria:

- Patients with a known history of hypersensitivity to original or reformulated Xyntha
or any component of the product.

- Patients with a known history of hypersensitivity to hamster protein.

- Patients participating in an interventional trial of any investigational drug or
device.